RxDoctor Payments Data

Bashar Brijawi, MD

Sleep Medicine · Cincinnati, OHNPI 1033198171

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $856 and has fallen 50.8% since, to $421 in 2025.

$2,840in general payments, 2019–2025

Across 136 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inogen, Inc.$585
  • Jazz Pharmaceuticals Inc.$501
  • GSK$327
  • Regeneron Healthcare Solutions, Inc.$265
  • Takeda Pharmaceuticals U.S.A., Inc.$160
  • Sanofi$157
  • plus $845 from 17 others

What the payments were for

  • Food & beverage$2,74096%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,840 in reported general payments places this provider in the 65th percentile of 94 sleep medicine providers in Ohio.

See all sleep medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$73,556
Medicare patients
394
Services billed
616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelsomraSuvorexant34$18,485
Doxepin Hcl157$6,013
Armodafinil44$1,893
Modafinil26$1,600
Trazodone Hcl17$818
Ropinirole Hcl53$814
Fluticasone Propionate23$277
Gabapentin18$174
Eszopiclone25$169
Olanzapine12$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$16$5812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 94 sleep medicine providers in Ohio.

Other sleep medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →